Enhanced penetration strategies for transdermal delivery

Abstract

Transdermal delivery offers several advantages in drug distribution, including convenience, painless administration, avoidance of first-pass metabolism, and ease of termination. However, the natural protective barriers of the skin, such as the stratum corneum, the topmost layer of skin, limit the systemic absorption of external therapeutics via transdermal delivery. Therefore, extensive application of transdermal delivery in medical treatment has been limited. Over the past few years, many formulation strategies and physical technologies, therefore, have been developed to enhance transdermal delivery. This review summarizes various formulation strategies proposed for transdermal delivery and their application in medical treatment.

Key words： transdermal delivery; stratum corneum; enhanced penetration; therapeutics

Acknowledgements

Xiaowen Liu acknowledges support by the startup funding from Jinan University and the Fundamental Research Funds for the Central Universities (No. 11618337), the National Natural Science Foundation of China (Grant No. 81903546).

References

1 Jin J F, Zhu L L, Xu H M, Wang H F, Feng X Q, Zhu X P, Zhou Q. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Preference and Adherence, 2015, 9: 923–942

2 Rowland M. Influence of route of administration on drug availability. Journal of Pharmaceutical Sciences, 1972, 61(1): 70–74

3 Duchěne D, Touchard F, Peppas N. Pharmaceutical and medical aspects of bioadhesive systems for drug administration. Drug Development and Industrial Pharmacy, 1988, 14(2-3): 283–318

4 Prausnitz M R, Langer R. Transdermal drug delivery. Nature Biotechnology, 2008, 26(11): 1261–1268

5 Prausnitz M R, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nature Reviews. Drug Discovery, 2004, 3(2): 115–124

6 Kalluri H, Banga A K. Transdermal delivery of proteins. AAPS PharmSciTech, 2011, 12(1): 431–441

7 Carter P, Narasimhan B, Wang Q. Biocompatible nanoparticles and vesicular systems in transdermal drug delivery for various skin diseases. International Journal of Pharmaceutics, 2019, 555: 49–62

8 Alkilani A, McCrudden M T, Donnelly R. Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics, 2015, 7(4): 438–470

9 Chen Y, Shen Y, Guo X, Zhang C, Yang W, Ma M, Liu S, Zhang M, Wen L P. Transdermal protein delivery by a coadministered peptide identified via phage display. Nature Biotechnology, 2006, 24(4): 455–460

10 Lopes L B, Garcia M T J, Bentley M V L. Chemical penetration enhancers. Therapeutic Delivery, 2015, 6(9): 1053–1061

11 Chen Y, Quan P, Liu X, Wang M, Fang L. Novel chemical permeation enhancers for transdermal drug delivery. Asian Journal of Pharmaceutical Sciences, 2014, 9(2): 51–64

12 Pham Q D, Björklund S, Engblom J, Topgaard D, Sparr E. Chemical penetration enhancers in stratum corneum—relation between molecular effects and barrier function. Journal of Controlled Release, 2016, 232: 175–187

13 Tscheik C, Blasig I E, Winkler L. Trends in drug delivery through tissue barriers containing tight junctions. Tissue Barriers, 2013, 1(2): e24565

14 Pathan I B, Setty C M. Chemical penetration enhancers for transdermal drug delivery systems. Tropical Journal of Pharmaceutical Research, 2009, 8(2): 173–179

15 Karande P, Jain A, Ergun K, Kispersky V, Mitragotri S. Design principles of chemical penetration enhancers for transdermal drug delivery. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102(13): 4688–4693

16 Haque T, Talukder M M U. Chemical Enhancer: A simplistic way to modulate barrier function of the stratum corneum. Advanced Pharmaceutical Bulletin, 2018, 8(2): 169–179

17 Ibrahim S A, Li S K. Efficiency of fatty acids as chemical penetration enhancers: Mechanisms and structure enhancement relationship. Pharmaceutical Research, 2010, 27(1): 115–125

18 Lane M E. Skin penetration enhancers. International Journal of Pharmaceutics, 2013, 447(1-2): 12–21

19 Kandimalla K, Kanikkannan N, Andega S, Singh M. Effect of Fatty acids on the permeation of melatonin across rat and pig skin in-vitro and on the transepidermal water loss in rats in-vivo. Journal of Pharmacy and Pharmacology, 1999, 51(7): 783–790

20 Aungst B J J, Rogers N, Shefter E. Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides. International Journal of Pharmaceutics, 1986, 33(1): 225–234

21 Aungst B J. Structure/Effect studies of fatty acid isomers as skin penetration enhancers and skin irritants. Pharmaceutical Research, 1989, 6(3): 244–247

22 Ongpipattanakul B, Burnette R R, Potts R O, Francoeur M L. Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharmaceutical Research, 1991, 8(3): 350–354

23 Babu R J, Chen L, Kanikkannan N. Fatty alcohols, fatty acids, and fatty acid esters as penetration enhancers. Springer Berlin Heidelberg location: Springer Berlin Heidelberg, 2015, 133–150

24 Parivesh S, Sumeet D, Abhishek D. Design, evaluation, parameters and marketed products of transdermal patches: A review. Journal of Pharmacy Research, 2010, 3(2): 235–240

25 Jordan W P Jr, Atkinson L E, Lai C. Comparison of the skin irritation potential of two testosterone transdermal systems: An investigational system and a marketed product. Clinical Therapeutics, 1998, 20(1): 80–87

26 Williams A C, Barry B W. Penetration enhancers. Advanced Drug Delivery Reviews, 2012, 64(Suppl): 128–137

27 Liu P, Cettina M, Wong J. Effects of isopropanol-isopropyl myristate binary enhancers on in vitro transport of estradiol in human epidermis: A mechanistic evaluation. Journal of Pharmaceutical Sciences, 2009, 98(2): 565–572

28 Watkinson R M, Herkenne C, Guy R H, Hadgraft J, Oliveira G, Lane M E. Influence of ethanol on the solubility, ionization and permeation characteristics of Ibuprofen in silicone and human skin. Skin Pharmacology and Physiology, 2009, 22(1): 15–21

29 Wischke C, Schwendeman S P. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. International Journal of Pharmaceutics, 2008, 364(2): 298–327

30 Andega S, Kanikkannan N, Singh M. Comparison of the effect of fatty alcohols on the permeation of melatonin between porcine and human skin. Journal of Controlled Release, 2001, 77(1): 17–25

31 Dias M, Naik A, Guy R H, Hadgraft J, Lane M E. In vivo infrared spectroscopy studies of alkanol effects on human skin. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69(3): 1171–1175

32 Jampilek J, Brychtova K. Azone analogues: Classification, design, and transdermal penetration principles. Medicinal Research Reviews, 2012, 32(5): 907–947

33 Harrison J E, Watkinson A C, Green D M, Hadgraft J, Brain K. The relative effect of azone and transcutol on permeant diffusivity and solubility in human stratum corneum. Pharmaceutical Research, 1996, 13(4): 542–546

34 Harrison J E, Groundwater P W, Brain K R, Hadgraft J. Azone® induced fluidity in human stratum corneum. A fourier transform infrared spectroscopy investigation using the perdeuterated analogue. Journal of Controlled Release, 1996, 41(3): 283–290

35 Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. International Journal of Pharmaceutics, 1999, 184(1): 1–6

36 Hadgraft J, Peck J, Williams D G, Pugh W J, Allan G. Mechanisms of action of skin penetration enhancers/retarders: Azone and analogues. International Journal of Pharmaceutics, 1996, 141(1): 17–25

37 Zou L L, Ma J L, Wang T, Yang T B, Liu C B. Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system. Current Neuropharmacology, 2013, 11(2): 197–208

38 Stalmans S, Bracke N, Wynendaele E, Gevaert B, Peremans K, Burvenich C, Polis I, De Spiegeleer B. Cell-penetrating peptides selectively cross the blood-brain barrier in vivo. PLoS One, 2015, 10(10): e0139652

39 Liu X, Zhang P, Rödl W, Maier K, Lächelt U, Wagner E. Toward artificial immunotoxins: Traceless reversible conjugation of RNase A with receptor targeting and endosomal escape domains. Molecular Pharmaceutics, 2017, 14(5): 1439–1449

40 Wagner E, Zenke M, Cotten M, Beug H, Birnstiel M L. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87(9): 3410–3414

41 Schwarze S R, Ho A, Vocero-Akbani A, Dowdy S F. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science, 1999, 285(5433): 1569–1572

42 Erazo-Oliveras A, Najjar K, Dayani L, Wang T Y, Johnson G A, Pellois J P. Protein delivery into live cells by incubation with an endosomolytic agent. Nature Methods, 2014, 11(8): 861–867

43 Kamada H, Okamoto T, Kawamura M, Shibata H, Abe Y, Ohkawa A, Nomura T, Sato M, Mukai Y, Sugita T, et al. Creation of novel cell-penetrating peptides for intracellular drug delivery using systematic phage display technology originated from Tat transduction domain. Biological & Pharmaceutical Bulletin, 2007, 30(2): 218–223

44 Tang H, Yin L, Kim K H, Cheng J. Helical poly(arginine) mimics with superior cell-penetrating and molecular transporting properties. Chemical Science (Cambridge), 2013, 4(10): 3839–3844

45 Lozano M V, Lollo G, Alonso-Nocelo M, Brea J, Vidal A, Torres D, Alonso M J. Polyarginine nanocapsules: A new platform for intracellular drug delivery. Journal of Nanoparticle Research, 2013, 15(3): 1515

46 Rothbard J B, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane P L, Wender P A, Khavari P A. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nature Medicine, 2000, 6(11): 1253–1257

47 Kim Y C, Ludovice P J, Prausnitz M R. Transdermal delivery enhanced by magainin pore-forming peptide. Journal of Controlled Release, 2007, 122(3): 375–383

48 Jung E, Lee J, Park J, Park D. Transdermal delivery of interferon-g (IFN-g) mediated by penetratin, a cell-permeable peptide. Biotechnology and Applied Biochemistry, 2005, 42(2): 169–173

49 Hsu T, Mitragotri S. Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108(38): 15816–15821

50 Lin C M, Huang K, Zeng Y, Chen X C, Wang S, Li Y. A simple, noninvasive and efficient method for transdermal delivery of siRNA. Archives of Dermatological Research, 2012, 304(2): 139–144

51 Candan G, Michiue H, Ishikawa S, Fujimura A, Hayashi K, Uneda A, Mori A, Ohmori I, Nishiki T I, Matsui H, Tomizawa K. Combining poly-arginine with the hydrophobic counter-anion 4-(1-pyrenyl)-butyric acid for protein transduction in transdermal delivery. Biomaterials, 2012, 33(27): 6468–6475

52 Gautam A, Nanda J S, Samuel J S, Kumari M, Priyanka P, Bedi G, Nath S K, Mittal G, Khatri N, Raghava G P S. Topical delivery of protein and peptide esing novel cell penetrating peptide IMT-P8. Scientific Reports, 2016, 6(1): 26278

53 Zhang T, Qu H, Li X, Zhao B, Zhou J, Li Q, Sun M. Transmembrane delivery and biological effect of human growth hormone via a phage displayed peptide in vivo and in vitro. Journal of Pharmaceutical Sciences, 2010, 99(12): 4880–4891

54 Chang M, Li X, Sun Y, Cheng F, Wang Q, Xie X, Zhao W, Tian X. Effect of cationic cyclopeptides on transdermal and transmembrane delivery of insulin. Molecular Pharmaceutics, 2013, 10(3): 951–957

55 Cevc G, Blume G. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Biochimica et Biophysica Acta (BBA)-. Biomembranes, 2001, 1514(2): 191–205

56 Cevc G, Schätzlein A, Blume G. Transdermal drug carriers: Basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides. Journal of Controlled Release, 1995, 36(1): 3–16

57 Al Shuwaili A H, Rasool B K A, Abdulrasool A A. Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 102: 101–114

58 Benson H A. Transfersomes for transdermal drug delivery. Expert Opinion on Drug Delivery, 2006, 3(6): 727–737

59 Jain S, Jain P, Umamaheshwari R, Jain N. Transfersomes—a novel vesicular carrier for enhanced transdermal delivery: Development, characterization, and performance evaluation. Drug Development and Industrial Pharmacy, 2003, 29(9): 1013–1026

60 Cevc G. Transdermal drug delivery of insulin with ultradeformable carriers. Clinical Pharmacokinetics, 2003, 42(5): 461–474

61 Rai S, Pandey V, Rai G. Transfersomes as versatile and flexible nano-vesicular carriers in skin cancer therapy: The state of the art. Nano Reviews & Experiments, 2017, 8(1): 1325708

62 Wang J, Wei Y, Fei Y R, Fang L, Zheng H S, Mu C F, Li F Z, Zhang Y S. Preparation of mixed monoterpenes edge activated PEGylated transfersomes to improve the in vivo transdermal delivery efficiency of sinomenine hydrochloride. International Journal of Pharmaceutics, 2017, 533(1): 266–274

63 Liu J, Li W, Teng H, Lin Z. Immunopharmacological action of sinomenine, an alkaloid isolated from Sinomenium acutum, and its mechanism of action in treating rheumatoid arthritis. Acta Pharmaceutica Sinica, 2005, 40(2): 127–131 (in Chinese)

64 Feng H, Yamaki K, Takano H, Inoue K, Yanagisawa R, Yoshino S. Effect of sinomenine on collagen-induced arthritis in mice. Autoimmunity, 2007, 40(7): 532–539

65 Han W, Li W, Wang X, Zhang H, Sun Y, Hao B. Preparation of sinomenine hydrochloride loaded nano flexible liposomes and their characteristics. Chinese Traditional and Herbal Drugs, 2011, 42(4): 671–675 (in Chinese)

66 Ward A, Clissold S P. Pentoxifylline. Drugs, 1987, 34(1): 50–97

67 Smith R V, Waller E S, Doluisio J T, Bauza M T, Puri S K, Ho I, Lassman H B. Pharmacokinetics of orally administered pentoxifylline in humans. Journal of Pharmaceutical Sciences, 1986, 75(1): 47–52

68 Rames A, Poirier J M, LeCoz F, Midavaine M, Lecocq B, Grange J D, Poupon R, Cheymol G, Jaillon P. Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clinical Pharmacology and Therapeutics, 1990, 47(3): 354–359

69 Bryce T, Chamberlain J, Hillbeck D, Macdonald C. Metabolism and pharmacokinetics of ¹⁴C-pentoxifylline in healthy volunteers. Arzneimittel-Forschung, 1989, 39(4): 512–517

70 Jiang T, Wang T, Li T, Ma Y, Shen S, He B, Mo R. Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma. ACS Nano, 2018, 12(10): 9693–9701

71 Bangham A D, Horne R. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. Journal of Molecular Biology, 1964, 8(5): 660–668

72 Petersen A L, Hansen A E, Gabizon A, Andresen T L. Liposome imaging agents in personalized medicine. Advanced Drug Delivery Reviews, 2012, 64(13): 1417–1435

73 Zhang P, He D, Klein P M, Liu X, Röder R, Döblinger M, Wagner E. Enhanced intracellular protein transduction by sequence defined tetra-oleoyl oligoaminoamides targeted for cancer therapy. Advanced Functional Materials, 2015, 25(42): 6627–6636

74 Eloy J O, Claro de Souza M, Petrilli R, Barcellos J P A, Lee R J, Marchetti J M. Liposomes as carriers of hydrophilic small molecule drugs: Strategies to enhance encapsulation and delivery. Colloids and Surfaces. B, Biointerfaces, 2014, 123: 345–363

75 Duong A D, Collier M A, Bachelder E M, Wyslouzil B E, Ainslie K M. One step encapsulation of small molecule drugs in liposomes via electrospray-remote loading. Molecular Pharmaceutics, 2016, 13(1): 92–99

76 Huwyler J, Wu D, Pardridge W M. Brain drug delivery of small molecules using immunoliposomes. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93(24): 14164–14169

77 Gregoriadis G, Neerunjun D E. Control of the rate of hepatic uptake and catabolism of liposome-entrapped proteins injected into rats. Possible therapeutic applications. European Journal of Biochemistry, 1974, 47(1): 179–185

78 Tan M L, Choong P F, Dass C R. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides, 2010, 31(1): 184–193

79 Chatin B, Mével M, Devallière J, Dallet L, Haudebourg T, Peuziat P, Colombani T, Berchel M, Lambert O, Edelman A, Pitard B. Liposome-based formulation for intracellular delivery of functional proteins. Molecular Therapy. Nucleic Acids, 2015, 4: e244

80 Rahimpour Y, Hamishehkar H. Liposomes in cosmeceutics. Expert Opinion on Drug Delivery, 2012, 9(4): 443–455

81 Sacha M, Faucon L, Hamon E, Ly I, Haltner-Ukomadu E. Ex vivo transdermal absorption of a liposome formulation of diclofenac. Biomedicine and Pharmacotherapy, 2019, 111: 785–790

82 Yang G, Lee H E, Shin S W, Um S H, Lee J D, Kim K B, Kang H C, Cho Y Y, Lee H S, Lee J Y. Efficient transdermal delivery of DNA nanostructures alleviates atopic dermatitis symptoms in NC/Nga mice. Advanced Functional Materials, 2018, 28(40): 1801918

83 Yamazaki N, Sugimoto T, Fukushima M, Teranishi R, Kotaka A, Shinde C, Kumei T, Sumida Y, Munekata Y, Maruyama K I, et al. Dual-stimuli responsive liposomes using pH- and temperature-sensitive polymers for controlled transdermal delivery. Polymer Chemistry, 2017, 8(9): 1507–1518

84 Donnelly R F, Singh T R R, Woolfson A D. Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety. Drug Delivery, 2010, 17(4): 187–207

85 Larrañeta E, McCrudden M T C, Courtenay A J, Donnelly R F. Microneedles: A new frontier in nanomedicine delivery. Pharmaceutical Research, 2016, 33(5): 1055–1073

86 Liu X, Wang C, Liu Z. Protein-engineered biomaterials for cancer theranostics. Advanced Healthcare Materials, 2018, 7(20): 1800913

87 Ye Y, Yu J, Wen D, Kahkoska A R, Gu Z. Polymeric microneedles for transdermal protein delivery. Advanced Drug Delivery Reviews, 2018, 127: 106–118

88 Waghule T, Singhvi G, Dubey S K, Pandey M M, Gupta G, Singh M, Dua K. Microneedles: A smart approach and increasing potential for transdermal drug delivery system. Biomedicine and Pharmacotherapy, 2019, 109: 1249–1258

89 Larrañeta E, Lutton R E M, Woolfson A D, Donnelly R F. Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development. Materials Science and Engineering R Reports, 2016, 104: 1–32

90 Moffatt K, Wang Y, Raj Singh T R, Donnelly R F. Microneedles for enhanced transdermal and intraocular drug delivery. Current Opinion in Pharmacology, 2017, 36: 14–21

91 McGrath M G, Vrdoljak A, O’Mahony C, Oliveira J C, Moore A C, Crean A M. Determination of parameters for successful spray coating of silicon microneedle arrays. International Journal of Pharmaceutics, 2011, 415(1): 140–149

92 Vrdoljak A, McGrath M G, Carey J B, Draper S J, Hill A V S, O’Mahony C, Crean A M, Moore A C. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. Journal of Controlled Release, 2012, 159(1): 34–42

93 Gill H S, Prausnitz M R. Coated microneedles for transdermal delivery. Journal of Controlled Release, 2007, 117(2): 227–237

94 Chen X, Corbett H J, Yukiko S R, Raphael A P, Fairmaid E J, Prow T W, Brown L E, Fernando G J P, Kendall M A F. Site-selectively coated, densely-packed microprojection array patches for targeted delivery of vaccines to skin. Advanced Functional Materials, 2011, 21(3): 464–473

95 Baek S H, Shin J H, Kim Y C. Drug-coated microneedles for rapid and painless local anesthesia. Biomedical Microdevices, 2017, 19(1): 2

96 Boehm R D, Miller P R, Hayes S L, Monteiro-Riviere N A, Narayan R J. Modification of microneedles using inkjet printing. AIP Advances, 2011, 1(2): 022139

97 Yao G, Quan G, Lin S, Peng T, Wang Q, Ran H, Chen H, Zhang Q, Wang L, Pan X, Wu C. Novel dissolving microneedles for enhanced transdermal delivery of levonorgestrel: In vitro and in vivo characterization. International Journal of Pharmaceutics, 2017, 534(1-2): 378–386

98 Wang C, Ye Y, Hochu G M, Sadeghifar H, Gu Z. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of Anti-PD1 antibody. Nano Letters, 2016, 16(4): 2334–2340

99 Johnson A R, Caudill C L, Tumbleston J R, Bloomquist C J, Moga K A, Ermoshkin A, Shirvanyants D, Mecham S J, Luft J C, De Simone J M. Single-step fabrication of computationally designed microneedles by continuous liquid interface production. PLoS One, 2016, 11(9): e0162518

100 Caudill C L, Perry J L, Tian S, Luft J C, Desimone J M. Spatially controlled coating of continuous liquid interface production microneedles for transdermal protein delivery. Journal of Controlled Release, 2018, 284: 122–132

101 Chen M C, Huang S F, Lai K Y, Ling M H. Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination. Biomaterials, 2013, 34(12): 3077–3086

102 Prausnitz M R, Mikszta J A, Cormier M, Andrianov A K. Microneedle-based Vaccines. Springer Berlin Heidelberg location: Springer Berlin Heidelberg, 2009, 369–393

103 Cheng G, Davoudi Z, Xing X, Yu X, Cheng X, Li Z, Deng H, Wang Q. Advanced silk fibroin biomaterials for cartilage regeneration. ACS Biomaterials Science & Engineering, 2018, 4(8): 2704–2715

104 Zhan Y, Zeng W, Jiang G, Wang Q, Shi X, Zhou Z, Deng H, Du Y. Construction of lysozyme exfoliated rectorite-based electrospun nanofibrous membranes for bacterial inhibition. Journal of Applied Polymer Science, 2015, 132(8): 41496

105 Xin S, Li X, Wang Q, Huang R, Xu X, Lei Z, Deng H. Novel layer-by-layer structured nanofibrous mats coated by protein films for dermal regeneration. Journal of Biomedical Nanotechnology, 2014, 10(5): 803–810